Abstract
Purpose
Obesity is a complex, chronic disease that is strongly associated with complications which cost the US healthcare system billions of dollars per year. Endoscopic sleeve gastroplasty (ESG) has emerged as a safe and effective procedure for treatment of obesity, but without practice guidelines there are likely to be variations practice. We sought to describe current practice patterns amongst endoscopists who perform ESG to help define areas of focus for future research and guideline development.
Methods
We conducted an anonymous cross-sectional survey to examine practice patterns related to ESG. The survey was organized in 5 sections: Endoscopic Practice, Training, and Resources; Pre-ESG Evaluation and Payment Model; Perioperative/Operative Period; Post-operative Period; and Endobariatric Practice Other Than ESG.
Results
A variety of exclusion criteria were reported by physicians performing ESG. Most respondents (n = 21/32, 65.6%) would not perform ESG for BMI under 27, and 40.6% (n = 13/32) would not perform ESG on patients with BMI over 50. The majority of respondents (74.2%, n = 23/31) reported ESG was not covered in their region, and most reported patients covered residual costs (67.7%, n = 21/31).
Conclusions
We found significant variability with respect to practice setting, exclusion criteria, pre-procedural evaluation, and medication use. Without guidelines for the selection of patients or standards for pre- and post-ESG care, substantial barriers to coverage will remain, and ESG will remain limited to those who can meet out-of-pocket costs. Larger studies are needed to confirm our findings, and future research should be focused on establishing patient selection criteria and standards in practices to provide guidance for endobariatric programs.
Graphical Abstract
Similar content being viewed by others
References
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.
Divino V, et al. Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study. J Manag Care Spec Pharm. 2021;27(2):210–22.
Hales CM, et al. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.
Heffron SP, et al. Treatment of Obesity in Mitigating Metabolic Risk. Circ Res. 2020;126(11):1646–65.
Khan Z, et al. Efficacy of Endoscopic Interventions for the Management of Obesity: a Meta-analysis to Compare Endoscopic Sleeve Gastroplasty, AspireAssist, and Primary Obesity Surgery Endolumenal. Obes Surg. 2019;29(7):2287–98.
Rogers AM, Pauli EM. Is endoscopic sleeve gastroplasty ready for prime time? Gastrointest Endosc. 2023;97(1):22–24.
Hedjoudje A, et al. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(5):1043-1053.e4.
Li P, et al. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: a meta-analysis. Surg Endosc. 2020;34(3):1253–60.
Lopez-Nava G, et al. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. Obes Surg. 2017;27(10):2649–55.
Sharaiha RZ et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol. 2021;19(5):1051–1057.
Singh S, et al. Safety and efficacy of endoscopic sleeve gastroplasty worldwide for treatment of obesity: a systematic review and meta-analysis. Surg Obes Relat Dis. 2020;16(2):340–51.
Abu Dayyeh BK, et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022;400(10350):441–51.
Alqahtani A, et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc. 2019;89(6):1132–8.
Hajifathalian K, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. Gastrointest Endosc. 2021;93(5):1110–8.
Campos GM, et al. ASMBS position statement on the rationale for performance of upper gastrointestinal endoscopy before and after metabolic and bariatric surgery. Surg Obes Relat Dis. 2021;17(5):837–47.
Yoon JY, et al. The Efficacy and Safety of Endoscopic Sleeve Gastroplasty as an Alternative to Laparoscopic Sleeve Gastrectomy. Clin Endosc. 2021;54(1):17–24.
Ahmed S, et al. Outcomes of Bariatric Surgery in Patients with Liver Cirrhosis: a Systematic Review. Obes Surg. 2021;31(5):2255–67.
Patton H, Heimbach J, McCullough A. AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol. 2021;19(3):436–45.
Ghoz H, et al. Endoscopic sleeve gastroplasty and postprocedural nutritional deficiencies: results from a single center exploratory study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):1039–41.
Badurdeen D, et al. The Attitude of Practitioners Towards Endoscopic Sleeve Gastroplasty. J Clin Gastroenterol. 2021;56(9):756–63.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
JDH declares no conflicts of interest.
JPA declares no conflicts of interest.
VG declares no conflicts of interest.
ARS reports compensation as a consultant for Apollo Endosurgery, Boston Scientific, Olympus, and MicroTech, and has received grant/research support funding from GI Dynamics and Fractyl.
JDH declares consultant relationships with Draupnir Bio, Gilead, Merck, Lilly, and Pfizer.
JS declares no conflicts of interest.
SEM declares no conflicts of interest.
MSM declares no conflicts of interest.
EMM declares no conflicts of interest.
AT declares no conflicts of interest.
Ethics Statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Key Points
• Endoscopic sleeve gastroplasty (ESG) has emerged as a safe and effective endoscopic procedure for treatment of obesity and obesity-related conditions.
• No formal guidelines for patient selection, procedural technique, or peri-procedural management exist.
• ESG practitioners have variable practice patterns which may in turn result in heterogenous outcomes.
• These factors contribute to procedural coverage barriers, resulting in substantial out-of-pocket costs to patients and a limited reach to eligible patients with obesity.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Haddad, J.D., Almandoz, J.P., Gomez, V. et al. Endoscopic Sleeve Gastroplasty: A Practice Pattern Survey. OBES SURG 33, 2434–2442 (2023). https://doi.org/10.1007/s11695-023-06684-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-023-06684-2